Radius Health (NASDAQ: RDUS) announced positive top-line data from the first six months of the ACTIVExtend trial that showed women ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Radius Health (RDUS) Trades to Session LowsOctober 12, 2015 2:41 PM Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With OsteoporosisOctober 12, 2015 2:30 PM Radius Health (RDUS), Dyax Corp (DYAX) Highlighted as Speculative Takeover PlaysOctober 12, 2015 12:06 PM Radius Health (RDUS) Presents Positive Phase 3 Data from ACTIVE Trial at ASBMR MeetingOctober 12, 2015 6:51 AM Radius Health Presents Positive Phase 3 Top-Line Data for Investigational Osteoporosis Therapy Abaloparatide at the American Society for Bone and Mineral Research 2015 Annual MeetingOctober 10, 2015 7:15 PM